MannKind to Present at the Cowen and Company Healthcare ...( VALENCIA Calif. March 13 /- MannK...),Health
Navigation Links
MannKind to Present at the Cowen and Company Healthcare Conference
Date:3/13/2008
VALENCIA, Calif., March 13 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Cowen and Company Healthcare Conference on March 17, 2008 at 3:15 PM ET at the Marriott Copley Place Hotel in Boston, MA.
Interested parties can access a link to the live web cast of the presentation in the Investor Relations section of the Company's website at http://www.mannkindcorp.com. A replay of the presentation will be available for 14 days.
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its lead product, the Technosphere(R) Insulin System, is currently in phase 3 clinical trials in the United States, Europe and Latin America to study its safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit http://www.mannkindcorp.com.
'/>"/>
| SOURCE MannKind Corporation Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. MannKind Corporation Reports Fourth Quarter and Full Year 2007 Financial Results
2. MannKind Corporation Reports Third Quarter Financial Results
3. MannKind to Present at Upcoming Conferences
4. MannKind Announces New $350 Million Credit Facility
5. Brookdale to Present at Lehman Global Healthcare Conference on March 19
6. Jazz Pharmaceuticals, Inc. Announces LUVOX CR Launch Plans and Reports Development Pipeline Progress at Investor Day Presentation
7. SURGEX(TM) Joins the Team of Sponsors for the PGA Tours 2008 Arnold Palmer Invitational Presented by MasterCard
8. HealthSouth to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference and the 2008 Credit Suisse Global Leveraged Finance Conference
9. Wellness Initiative for 2008 Tour de Georgia Presented by AT&T Led by New Partnership With Blue Cross and Blue Shield of Georgia
10. Sunesis Pharmaceuticals to Present at Healthcare Investor Conferences in March
11. Medivation to Present at Cowen and Companys 28th Annual Health Care Conference
Post Your Comments:
(Date:7/23/2008)...ears Even Though Some Kilns Emit More,Mercury Than...L, CA, IA,IL, MD, MI, MT, NY, OR, SC, TX and WA.,... For more than a decade,after Congress told it to ... across the nation, the U.S. Environmental Protect...w study from Earthjustice and the,Environmental In...
(Date:7/23/2008)... Biodiversity has long been recognized by EPA as c... on healthy ecosystems to provide food, clean air,...onnection between disease and biodiversity (the nu...geographic region). Recent studies suggest that m...eases such as Lyme disease and West Nile encephali...
(Date:7/23/2008)...e/ -- Mercy Health Plans, the St.,Louis-based heal...the,Sisters of Mercy Health System, has announced ...plans to: Mercy MedicareAdvantage. The plans, whic...d Southwest Missouri,previously were offered usin...John,s PremierPlus and St. John,s PremierPlus Opti...
(Date:7/23/2008)...knowledge that regular exercise supports physical ...tions from health care providers, the majority of ...n a new study, University of Missouri researchers ...d interventions focused on behavior-changing strat...ity levels. In contrast, interventions based on co...
Breaking Medicine News(10 mins):Health News:Earthjustice/EIP Report: Dangerous Mercury Pollution From Unregulated Cement Kilns in U.S. About Twice as High as Levels Previously Projected by EPA 2Health News:Earthjustice/EIP Report: Dangerous Mercury Pollution From Unregulated Cement Kilns in U.S. About Twice as High as Levels Previously Projected by EPA 3Health News:Earthjustice/EIP Report: Dangerous Mercury Pollution From Unregulated Cement Kilns in U.S. About Twice as High as Levels Previously Projected by EPA 4Health News:Earthjustice/EIP Report: Dangerous Mercury Pollution From Unregulated Cement Kilns in U.S. About Twice as High as Levels Previously Projected by EPA 5Health News:Earthjustice/EIP Report: Dangerous Mercury Pollution From Unregulated Cement Kilns in U.S. About Twice as High as Levels Previously Projected by EPA 6Health News:Earthjustice/EIP Report: Dangerous Mercury Pollution From Unregulated Cement Kilns in U.S. About Twice as High as Levels Previously Projected by EPA 7Health News:Could preserving biodiversity reduce disease? 2Health News:Making patients move requires the right exercise advice 2[0] Earthjustice/EIP Report: Dangerous Mercury Pollution From Unregulated Cement Kilns in U.S. About Twice as High as Levels Previously Projected by EPA[0] Could preserving biodiversity reduce disease?[0] Mercy Health Plans Announces New Name for Their Medicare Advantage Plans: Mercy Medicare Advantage[0] Making patients move requires the right exercise advice
...ated injury experts from eight countries that have... and discussed their emergency medical response to...uld be used by others to enhance preparedness. Th..., Indonesia, Iraq, Israel, United Kingdom, United ...
...FDA) today announced that manufacturers of pergoli...n’s disease, will voluntarily remove// these drugs...mage to patients’ heart valves. The products bein... for pergolide marketed by Valeant Pharmaceuticals...
...ster have discovered that arthritis pain, unlike t... in the //parts of the brain concerned with emotio...captured the first images of how the brain process...sion tomography (PET) scanners based at the Christ...
...ss has said the country’s healthcare sector would ... New avenues of opportunity within healthcare itse...icant growth driver, the minister said while addre... students and researchers at the Boston University...
Other Medicine News:Health News:International Study Finds Ways to Maximize Effective Responses After Terrorism Incidents 2Health News:International Study Finds Ways to Maximize Effective Responses After Terrorism Incidents 3Health News:FDA Announces Voluntary Withdrawal of Pergolide Products 2Health News:Arthritis Pain Processed in Brain’s 'fear Zone,' First PET Scans Revea 2(Date:7/23/2008)... Company Focused on IND-Enabling Work with Protei... Pathway of Complement System, CAMBRIDGE, Mass., ...today announced it has initiated a corporate growt...D., as chief executive officer and the,establishme...niker succeeds,Woodruff Emlen, M.D., a co-founder ...
(Date:7/22/2008)... Latest awards under Therapeutics Development Ini...borations to 23; next deadline January 20,2009, ...rt of its mission to,speed delivery of transformat... The Michael J. Fox Foundation for Parkinson,s Res... six industry research teams. The awards,were gran...
(Date:7/22/2008)... Two Regimens Including Lantus(R) and Apidra(R) Re...ts with Type 2 Diabetes, Whatever the Algorithm ... N.J., July 22 /- Results from the "A...a Simple Algorithm to Carbohydrate,Counting for Ad...e,published in the American Diabetes Association,s...
(Date:7/22/2008)...st Developed and Validated by Columbia University ..., Proprietary MicroRNA Technology, The Test Diff...ll Lung Cancer (NSCLC), Classifying Squamous-Cell...96 Percent and Specificity of 90 Percent,This is t...NAs, Sensitivity as Biomarkers for Accura...
Breaking Medicine Technology:Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 2First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 5Invasion of the brain tumors 41 1Features of replication suggest viruses have common themes vulnerabilities 38 1Features of replication suggest viruses have common themes vulnerabilities 38 2Features of replication suggest viruses have common themes vulnerabilities 38 3Clones on task serve greater good evolutionary study shows 35 1Clones on task serve greater good evolutionary study shows 35 2Unravelling new complexity in the genome 32 1Unravelling new complexity in the genome 32 2[0] Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters[0] Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics[0] Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes[1] First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval
...rtments, REINACH and BASEL, Switzerland, March 29,...announced promising,results of "first-in-man" stud...se studies included a total of 19 healthy male,vol...ever using Microdosing,for the determination of dr...s showed that AR-709 achieves high concentrations ...
...ADIA Pharmaceuticals,Inc. (Nasdaq: ACAD), a biopha...y to fuel drug discovery and clinical,development ...orders, today announced that the company will pres...renia Research, held from,March 28 through April 1...ns will cover ACADIA,s two schizophrenia programs ...
Other Medicine Technology:Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 2Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 3Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 4Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 5ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 2ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 3ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 4ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 5...g; medication nebulizer achieves optimum lung pene...d MMAD particle size range is 1.04-1.10 µ at...essor or air outlet., ,As the world leader in air...providers the assurance of proven technology by of...
...rs breakthrough continuous low-flow nebulizer perf...ozzle technology allows for optimal medication and...I~NEB takes on severe asthma, COPD and pneumonia i...gure with a mask, mouth and T-piece to deliver hig...
...ication nebulizers offer a spill-proof design and ... angle. All medical nebulizers are free-standing f...ations are available., ,All Portex® medicatio...g; medication nebulizers feature consistently fine...
...ication nebulizers offer a spill-proof design and ... angle. All medical nebulizers are free-standing f...ations are available., ,All Portex® medicatio...g; medication nebulizers feature consistently fine...
Medicine Products:| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |